Insider Buying Report: SAVA and BCDA
PorAinvest
martes, 23 de septiembre de 2025, 10:47 am ET1 min de lectura
BCDA--
Cassava Sciences (SAVA)
Cassava Sciences shares are trading higher on Tuesday, with a 19.61% increase to $2.77. The stock has a 52-week high of $33.98 and a 52-week low of $1.15. The insider purchase by CEO Richard Barry is viewed as a vote of confidence in the company's future, following the recent halt in the development of its Alzheimer’s drug, simufilam, after the Phase 3 REFOCUS-ALZ trial failed to meet its primary endpoints [1].
BioCardia (BCDA)
BioCardia shares are also experiencing a rebound, up 11.7% on Tuesday to $1.25. The stock has a 52-week high of $1.63 and a 52-week low of $0.90. Director Simon H. Stertzer's purchase is seen as a positive signal, especially given the company's recent financial challenges and market pressures [2].
Both companies have faced significant market challenges, with Cassava Sciences' stock collapsing by over 91% in the past year due to the trial failure of simufilam, and BioCardia's stock falling 32.38% in the past week. The insider purchases are a sign of optimism among key executives and may indicate a potential turnaround for both companies.
References
[1] https://www.benzinga.com/trading-ideas/movers/25/09/47819841/cassava-sciences-sava-stock-is-surging-tuesday-whats-going-on
[2] https://www.investing.com/news/company-news/biocardia-prices-6-million-public-offering-of-common-stock-and-warrants-93CH-4245076
SAVA--
Two notable insider buys have been reported: Cassava Sciences (SAVA) CEO Richard Barry purchased 237,941 shares for $534,743, and BioCardia (BCDA) Director Simon H. Stertzer bought 398,400 shares for $498,000. Both purchases occurred on Friday and mark the first buy for Barry and the fourth buy for Stertzer in the past year. SAVA is up 19.8% and BCDA is up 11.7% on Tuesday.
Two significant insider buys have been reported this week, contributing to the upward movement of Cassava Sciences (SAVA) and BioCardia (BCDA) stocks. On Friday, Cassava Sciences CEO Richard Barry purchased 237,941 shares at an average price of $2.25 each, while BioCardia Director Simon H. Stertzer bought 398,400 shares at an average price of $1.25 each. Both purchases occurred on the same day and mark the first buy for Barry and the fourth buy for Stertzer in the past year.Cassava Sciences (SAVA)
Cassava Sciences shares are trading higher on Tuesday, with a 19.61% increase to $2.77. The stock has a 52-week high of $33.98 and a 52-week low of $1.15. The insider purchase by CEO Richard Barry is viewed as a vote of confidence in the company's future, following the recent halt in the development of its Alzheimer’s drug, simufilam, after the Phase 3 REFOCUS-ALZ trial failed to meet its primary endpoints [1].
BioCardia (BCDA)
BioCardia shares are also experiencing a rebound, up 11.7% on Tuesday to $1.25. The stock has a 52-week high of $1.63 and a 52-week low of $0.90. Director Simon H. Stertzer's purchase is seen as a positive signal, especially given the company's recent financial challenges and market pressures [2].
Both companies have faced significant market challenges, with Cassava Sciences' stock collapsing by over 91% in the past year due to the trial failure of simufilam, and BioCardia's stock falling 32.38% in the past week. The insider purchases are a sign of optimism among key executives and may indicate a potential turnaround for both companies.
References
[1] https://www.benzinga.com/trading-ideas/movers/25/09/47819841/cassava-sciences-sava-stock-is-surging-tuesday-whats-going-on
[2] https://www.investing.com/news/company-news/biocardia-prices-6-million-public-offering-of-common-stock-and-warrants-93CH-4245076
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema
Comentarios
Aún no hay comentarios